In Russia, the Use of Premium-Priced Novel Agents Will Expand the Acute Coronary Syndrome Market Through 2017 Despite Market Constraints in Russia, Multinational Corporations Will Enjoy Significant Sales Growth for Key Products, According to a New Report from Decision Resources
BURLINGTON, Mass., Oct. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the acute coronary syndrome (ACS) market in Russia will grow at an annual rate of more than five percent, reaching $360 million in 2017. The Emerging Markets report entitled Acute Coronary Syndrome in Russia finds that the use of key branded agents in the acute and posthospital settings and a reliance on polypharmacy regimens will drive growth in this market.
Between 2012 and 2017, the negative financial impact of the ongoing generic erosion of Sanofi's Plavix will be offset by the switch to AstraZeneca's Brilinta and the launch and use of Eli Lilly/Daiichi-Sankyo's Efient and The Medicines Company's cangrelor. Additionally, the anticipated emergence of Bayer/Janssen's oral factor Xa antagonist Xarelto and Merck's thrombin receptor antagonist vorapaxar will expand the treatment armamentarium for ACS management.
"Our survey of Russian cardiologists reveals that the government pays for the majority of ACS drugs available in Russia, and despite price controls on some drugs, the strength of emerging therapies' clinical data and cardiologists' preference for branded products should translate into healthy near-term growth in the Russian ACS market," said Decision Resources Analyst Natalia Reoutova.
The report also finds that Russia will see an increase in the annual number of diagnosed events of ACS through 2022 predominantly due to aging of the country's population.
The new report features extensive primary research with Russian cardiologists as well as a market outlook through 2017.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources